ARCH BIOPARTNERS RECEIVES CENTRAL IRB APPROVAL TO SUPPORT U.S. SITES IN PHASE II CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY TRIAL OF LSALT PEPTIDE

Reuters · 1d ago

Please log in to view news